Clinical Outcomes of Thoracic Cancer Patients Requiring ICU Admission: A 10-Year Retrospective Study
DOI:
https://doi.org/10.82582/thorac.67Keywords:
lung cancer, Immune Checkpoint Inhibitors/therapeutic use, intensive care unit, outcomesAbstract
Introduction
Lung cancer is the most common solid malignancy requiring intensive care unit (ICU) admission, but ICU admission for cancer patients is often denied, being the second most common reason for refusal. This study aimed to evaluate the outcomes of thoracic cancer patients admitted to the ICU and understand the characteristics that may affect these outcomes.
Methods
This retrospective cohort study analyzed 25 patients with lung cancer admitted to the ICU between 2014 and 2023 at the Multidisciplinary Thoracic Tumors Unit of a tertiary hospital in Portugal. Clinical characteristics and survival outcomes were assessed.
Results
Patients had a median age of 68 years, were predominantly male (72%), and mostly had stage IV disease (76%). Over 10 years, ICU admissions for thoracic cancer patients increased, with septic shock being the primary reason for admission. Respiratory and cardiovascular dysfunctions were prevalent, requiring frequent respiratory support. Mortality rates were 60% at 28 days, 72% at 6 months, and 76% at 12 months. Higher SOFA and SAPS II scores, hematological dysfunction, and invasive mechanical ventilation were associated with higher 28-day mortality.
Conclusion
ICU mortality was linked to severity at admission, not oncological disease burden. Survivors maintained functional status and continued treatment. Advancements in lung cancer therapies and rising survival rates emphasize the need to update ICU admission criteria and mortality predictor scores.
Downloads
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49. doi: 10.3322/caac.21660.
Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5:288–300. doi: 10.21037/tlcr.2016.06.07.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7–33. doi: 10.3322/caac.21654.
Guerreiro T, Forjaz G, Antunes L, Bastos J, Mayer A, Aguiar P, et al. Lung cancer survival and sex-specific patterns in Portugal: A population-based analysis. Pulmonology. 2023;29:S70–9. doi: 10.1016/j.pulmoe.2021.09.001.
Bareschino MA, Schettino C, Rossi A, Maione P, Sacco PC, Zeppa R, et al. Treatment of advanced non small cell lung cancer. J Thorac Dis. 2011;3:122-33. doi: 10.3978/j.issn.2072- 1439.2010.12.08.
Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019; 11:943–53. doi: 10.2147/CMAR.S187317.
Dillman RO, McClure SE. Steadily Improving Survival in Lung Cancer. Clin Lung Cancer. 2014;15:331–7. doi: 10.1016/j. cllc.2014.05.006.
Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:339–57. doi: 10.1016/j. annonc.2022.12.013.
Lu C, Tan Y. Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party. Mol Ther Oncol. 2024;32:200773. doi: 10.1016/j.omton.2024.200773.
Puxty K, McLoone P, Quasim T, Sloan B, Kinsella J, Morrison DS. Risk of Critical Illness Among Patients With Solid Cancers. JAMA Oncol. 2015;1:1078. doi: 10.1001/jamaoncol.2015.2855.
Azoulay E, Schellongowski P, Darmon M, Bauer PR, Benoit D, Depuydt P, et al. The Intensive Care Medicine research agenda on critically ill oncology and hematology patients. Intensive Care Med. 2017;43:1366–82. doi: 10.1007/s00134-017-4884-z.
Soares M, Caruso P, Silva E, Teles JM, Lobo SM, Friedman G, et al. Characteristics and outcomes of patients with cancer requiring admission to intensive care units: a prospective multicenter study. Crit Care Med. 2010;38:9–15. doi: 10.1097/ CCM.0b013e3181c0349e.
1Qian J, Qin R, Hong L, Shi Y, Yuan H, Zhang B, et al. Characteristics and clinical outcomes of patients with lung cancer requiring ICU admission: a retrospective analysis based on the MIMIC-III database. Emerg Cancer Care. 2023;2:1.
Anisoglou S, Asteriou C, Barbetakis N, Kakolyris S, Anastasiadou G, Pnevmatikos I. Outcome of lung cancer patients admitted to the intensive care unit with acute respiratory failure. Hippokratia. 2013;17:60–3.
Müller AM, Gazzana MB, Silva DR. Outcomes for patients with lung cancer admitted to intensive care units. Rev Bras Ter Intensiva. 2013;25:12–6.
Aygencel G, Turkoglu M, Turkoz Sucak G, Benekli M. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. J Crit Care. 2014;29:618–26. doi: 10.1016/j. jcrc.2014.01.014.
Taccone FS, Artigas AA, Sprung CL, Moreno R, Sakr Y, Vincent JL. Characteristics and outcomes of cancer patients in European ICUs. Crit Care. 2009;13:R15.
Puxty K, McLoone P, Quasim T, Kinsella J, Morrison D. Survival in solid cancer patients following intensive care unit admission. Intensive Care Med. 2014;40:1409–28.
Hofhuis JGM, Schrijvers AJ, Schermer T, Spronk PE. Healthrelated quality of life in ICU survivors—10 years later. Sci Rep. 2021;11:15189. doi: 10.1038/s41598-021-94637-z.
García de Herreros M, Laguna JC, Padrosa J, Barreto TD, Chicote M, Font C, et al. Characterisation and Outcomes of Patients with Solid Organ Malignancies Admitted to the Intensive Care Unit: Mortality and Impact on Functional Status and Oncological Treatment. Diagnostics. 2024;14:730. doi: 10.3390/diagnostics14070730.
Hulse K, Quasim T, Morrison D, MacLoone P, Sloane B, Kinsella J, et al. Characteristics and outcomes of lung cancer patients after intensive care admission. J Intensive Care Soc. 2015;16:239–9. doi: 10.1177/1751143715583857.
Soares M, Darmon M, Salluh JI, Ferreira CG, Thiéry G, Schlemmer B, et al. Prognosis of Lung Cancer Patients With Life-Threatening Complications. Chest. 2007;131:840–6. doi: 10.1378/chest.06-2244.
Bonomi MR, Smith CB, Mhango G, Wisnivesky JP. Outcomes of elderly patients with stage IIIB–IV non-small cell lung cancer admitted to the intensive care unit. Lung Cancer. 2012;77:600– 4. doi: 10.1016/j.lungcan.2012.05.103.
Reichner CA, Thompson JA, O’Brien S, Kuru T, Anderson ED. Outcome and Code Status of Lung Cancer Patients Admitted to the Medical ICU. Chest. 2006;130:719–23.
Slatore CG, Cecere LM, LeTourneau JL, O’Neil ME, Duckart JP, Wiener RS, et al. Intensive Care Unit Outcomes Among Patients With Lung Cancer in the Surveillance, Epidemiology, and End Results–Medicare Registry. J Clin Oncol. 2012;30:1686–91.
Kim YJ, Kim MJ, Cho YJ, Park JS, Kim JW, Chang H, et al. Who should be admitted to the intensive care unit? The outcome of intensive care unit admission in stage IIIB–IV lung cancer patients. Med Oncol. 2014;31:847. doi: 10.1007/s12032-014-0847-1.
Manjappachar NK, Cuenca JA, Ramírez CM, Hernandez M, Martin P, Reyes MP, et al. Outcomes and Predictors of 28-Day Mortality in Patients With Hematologic Malignancies and Septic Shock Defined by Sepsis-3 Criteria. J Natl Compr Canc Netw. 2022;20:45–53. doi: 10.6004/jnccn.2021.7046.
Hulse K, Quasim T, Morrison D, MacLoone P, Sloane B, Kinsella J, et al. Characteristics and outcomes of lung cancer patients after intensive care admission. J Intensive Care Soc. 2015;16:239–9.
Toffart AC, M’Sallaoui W, Jerusalem S, Godon A, Bettega F, Roth G, et al. Quality of life of patients with solid malignancies at 3 months after unplanned admission in the intensive care unit: A prospective case-control study. PLoS One. 2023;18:e0280027. doi: 10.1371/journal.pone.0280027.
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378:113-25. doi: 10.1056/NEJMoa1713137.
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382:41- 50. doi: 10.1056/NEJMoa1913662.
Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, et al. Updated overall survival and final progressionfree survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31:1056–64. doi: 10.1016/j.annonc.2020.04.478.
Solomon BJ, Liu G, Felip E, Mok TS, Soo RA, Mazieres J, et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. J Clin Oncol. 2024;42:3400–9. doi: 10.1200/JCO.24.00581.
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375:1823-33. doi: 10.1056/NEJMoa1606774.
Shalata W, Zolnoorian J, Migliozzi G, Jama AA, Dudnik Y, Cohen AY, et al. Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience. Int J Mol Sci. 2023;24:5938. doi: 10.3390/ijms24065938.
3Chien CR, Chen HJ. Lazarus response to treatment of patients with lung cancer and oncogenic mutations in the intensive care unit. J Thorac Dis. 2016;8:E1455–61.
Takeda T, Itano H, Takeuchi M, Nishimi Y, Saitoh M, Takeda S. Osimertinib administration via nasogastric tube in an EGFRT790M‐ positive patient with leptomeningeal metastases. Respirol Case Rep. 2017;5:e00241. doi: 10.1002/rcr2.241.
Downloads
Published
Data Availability Statement
This work has not been made available in any other scientific journal
Issue
Section
License
Copyright (c) 2026 Author(s) (or their employer(s)) and THORAC 2024
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
